Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) EPS (Weighted Average and Diluted) (2020 - 2024)

Immuneering (IMRX) has 5 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.59 in Q4 2024.

  • For Q4 2024, EPS (Weighted Average and Diluted) fell 15.69% year-over-year to -$0.59; the TTM value through Dec 2024 reached -$2.04, down 8.51%, while the annual FY2024 figure was -$2.04, 8.51% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.59 in Q4 2024 per IMRX's latest filing, down from -$0.49 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.88 in Q4 2021 and bottomed at -$1.61 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.58, with a median of -$0.49 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 174.58% in 2021, then plummeted 156.82% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.18 in 2020, then skyrocketed by 174.58% to $0.88 in 2021, then plummeted by 156.82% to -$0.5 in 2022, then dropped by 2.0% to -$0.51 in 2023, then dropped by 15.69% to -$0.59 in 2024.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.59 in Q4 2024, -$0.49 in Q3 2024, and -$0.47 in Q2 2024.